(Q37942705)

25 August 2017

1 reference

title

An old friend in a new light: the role of osteocalcin in energy metabolism (English)

1 reference

25 August 2017

1 reference

Gustavo Duque

2

0 references

author name string

Tim R Sullivan

series ordinal

1

1 reference

25 August 2017

Anthony C Keech

series ordinal

3

1 reference

25 August 2017

Markus Herrmann

series ordinal

4

1 reference

25 August 2017

publication date

5 October 2011

1 reference

Cardiovascular Therapeutics

25 August 2017

published in

1 reference

25 August 2017

volume

31

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

65-75

1 reference

Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Endocrine regulation of energy metabolism by the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Body mass index as a predictor of fracture risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Expanding the functional spectrum of vitamin K in bone. Focus on: "Vitamin K promotes mineralization, osteoblast to osteocyte transition, and an anti-catabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Vitamin K-dependent carboxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Measurement of osteocalcin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Diurnal variation in total and undercarboxylated osteocalcin: influence of increased dietary phylloquinone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

An ELISA-based method to quantify osteocalcin carboxylation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Leptin regulation of bone resorption by the sympathetic nervous system and CART

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Leptin regulates bone formation via the sympathetic nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Caloric restriction decreases cortical bone mass but spares trabecular bone in the mouse skeleton: implications for the regulation of bone mass by body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Leptin and the sympathetic connection of fat to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Relationships between fat and bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Cloning of hOST-PTP: the only example of a protein-tyrosine-phosphatase the function of which has been lost between rodent and human.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Tyrosine-specific protein kinase activity is associated with the purified insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Co-dependence of bone and energy metabolisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Correlations between insulin sensitivity and bone mineral density in non-diabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Bone mass in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Insulin-like growth factor (IGF) and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Association between serum osteocalcin and markers of metabolic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Relationship between osteocalcin and glucose metabolism in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effect of diet-induced weight loss on total body bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effect of voluntary weight loss on bone mineral density in older overweight women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Bone minerals changes in obese women during a moderate weight loss with and without calcium supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Bone loss accompanying voluntary weight loss in obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Bone mineral density during reduction, maintenance and regain of body weight in premenopausal, obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Protection of bone mass by estrogens and raloxifene during exercise-induced weight Loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Weight-bearing, aerobic exercise increases markers of bone formation during short-term weight loss in overweight and obese men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Calcium supplementation suppresses bone turnover during weight reduction in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Gastric banding induces negative bone remodelling in the absence of secondary hyperparathyroidism: potential role of serum C telopeptides for follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Weight loss-induced alterations in serum markers of bone turnover persist during weight maintenance in obese men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Bone metabolism in male patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Molecular mechanisms of action of bisphosphonates: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Raloxifene and cardiovascular health: its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Sex steroids increase cholesterol 7alpha-hydroxylase mRNA in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Bone mineral density, osteocalcin, and bone-specific alkaline phosphatase in patients with insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Diabetes and risk of fracture: The Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Older women with diabetes have an increased risk of fracture: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Older women with diabetes have a higher risk of falls: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Pluripotency of mesenchymal stem cells derived from adult marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

PPAR-gamma regulates osteoclastogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

The effect of fluvastatin on parameters of bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Short-term reduction in bone markers with high-dose simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

HMG-CoA reductase inhibitors and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Statins and fracture risk. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effects of statins on bone mineral density: a meta-analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Beyond the laboratory: clinical implications for statin pleiotropy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Stimulation of bone formation in vitro and in rodents by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00300.X

10.1111/J.1755-5922.2011.00300.X

21 January 2018

Identifiers

DOI

1 reference

release_rfkfjjy26zdq7dqay7va6cv4cy

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rfkfjjy26zdq7dqay7va6cv4cy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference